Skip to content
PICO Portalanswers from OpenAlex

Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial

PaperCitations, authors & open-access status

Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial is a paper indexed in PICO Portal from OpenAlex.

How many citations does Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial have?

PICO Portalcitation count

Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial has 545 citations in the OpenAlex counts PICO Portal stores.

When was Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial published?

PICO Portalyear

Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial has 2012 year in the PICO Portal index.

What is the open-access status of Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial?

PICO Portaloa status

Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial has green oa status in the PICO Portal index.

What is the DOI of Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial?

PICO Portaldoi

The DOI for Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial is on the source record.

What is the PMID of Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial?

PICO Portalpmid

The PMID for Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial is on the source record.

What is the OpenAlex record for Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial?

PICO Portalopenalex

The OpenAlex for Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial is on the source record.

Related on PICO Portal

470M+ articles · 14-day free trial